Leber Congenital Amaurosis clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
The Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
open to eligible people ages 6 years and up
To assess the safety of unilateral subretinal administration of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (LCA10).